Annual awards recognize industry's most successful campaigns, initiatives, people, and teamsBALTIMORE, Dec. 9, 2025 /PRNewswire/ -- Sage Growth Partners (Sage), a...
US cancer center partners with Syantra Inc. for further testing of Onco-ID Breast, a whole blood mRNA test for hyper-early...
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder...
The newly offered, targeted ozone injections are a minimally invasive therapy with potential benefits for prostate tissue and function GREENVILLE,...
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting...
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models,...
New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trialsBAR HARBOR, Maine, Dec....
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates...
Lingo, Abbott's first over-the-counter biowearable, expands to Android devicesContinuous glucose monitoring devices help people maintain healthy glucose levels, which are...
Board includes internationally recognized physicians and scientists from Dana-Farber Cancer Institute, George Washington University, Mayo Clinic, Montefiore Einstein Comprehensive Cancer...
MESA, ARIZONA / ACCESS Newswire / December 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is thrilled to announce...
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in...
Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was...
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings,...
-6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI...
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines of therapy, with no new...
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent...
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted...